Comparing standard and high doses of buprenorphine for opioid addiction treatment.
Official title: CCC TO 11 - CTN-0145: STANDARD VERSUS HIGH DOSE ED-INITIATED BUPRENORPHINE INDUCTION. POP: 8/28/23 - 8/27/27.
Funded at The Emmes Company, LLC · NIH-11219441 · Data updated 2026-11-12
This study is looking at whether a regular or higher dose of buprenorphine works better for people starting treatment for opioid addiction, and it's designed for anyone who wants help with their addiction.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | The Emmes Company, LLC NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | August 28, 2023 |
| Project end | August 27, 2025 |
| Funding year | 2024 |
| Award (this year) | $256,829 |
| NIH project number | 75N95020D00012-P00001-759502300004-2 |
| Project ID | NIH-11219441 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with opioid use disorder who are seeking treatment.
✕Less likely to help
Patients who are not struggling with opioid addiction or who are not seeking treatment may not benefit from this research.
What this research studies
This research investigates the effectiveness of standard versus high doses of buprenorphine in initiating treatment for individuals struggling with opioid addiction. Participants will receive either dosage to determine which is more effective in helping them manage their addiction. The study is part of the NIH's HEAL initiative, which aims to find rapid and effective solutions to the opioid crisis. Patients will be monitored throughout the treatment process to assess outcomes and improve future treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for individuals with opioid addiction, potentially improving recovery rates.
How similar studies have gone: Previous research has shown promising results in using buprenorphine for opioid addiction treatment, indicating that this approach has potential for success.
Where this research is happening
-
The Emmes Company, LLC
Rockville, United States Active
Researchers
- Principal investigator: Jelstrom, Eve — The Emmes Company, LLC
- Study coordinator: Jelstrom, Eve
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.